Cellular Immunity in the Treatment of Brain Tumors

摘要

Malignant brain tumors are among the gravest forms of cancer. The most common of these incurable tumors, glioblastoma multiforme (GBM), is responsible for 50(percent) of all intracranial gliomas and 25(percent) of intracranial tumors in adults. GBM diagnosis carries with it an average survival between 12 and 18 months (with 90-95(percent) of patients surviving less than 2 years), without the possibility of spontaneous remission or effective treatment. The consistently short survival and absence of spontaneous remission that makes GBM such a devastating disease also renders the evaluation of new therapies for this disease relatively rapid and unequivocal. Overall survival represents the standard by which therapies for GBM are evaluated, in part because tumor mass reduction (i.e., surgically) does not necessarily correlate with prolonged survival.